Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cultured chondrocytes - Vericel

Drug Profile

Autologous cultured chondrocytes - Vericel

Alternative Names: Articel; Autologous cultured chondrocytes on porcine collagen membrane; MACI; MACI Implant; Matrix-applied-characterised-autologous-cultured-chondrocytes-Vericel; Matrix-induced autologous chondrocyte implant

Latest Information Update: 23 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verigen AG
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries
  • Phase II Osteonecrosis

Most Recent Events

  • 17 Jul 2018 Phase-III clinical trials in Knee injuries (In adolescents, In children) in USA (Parenteral) (NCT03588975)
  • 23 Mar 2018 Interim efficacy and adverse events data from a SUMMIT extension trial in Knee injuries released by Vericel
  • 10 May 2017 Autologous cultured chondrocytes - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other South-East Asia countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top